

EQA round: AIM2/24 - Autoimmunity

Deadline: 27.9.2024

Setup: Slovakia

AV = assigned value	N _{tot} = total number of the results	N _{eva} = number of the results assessed
CVP = consensus of all participants	N _{rel} = relative number of the results	N _{suc} = number of successful results
>>> ... expected result		S _{rel} = relative success
> ... acceptable result		
± ... result not assessed		

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
Set 1							
(560) ANA screening (antibodies against cell nucleus) - prove		17			17	17	100
Sample A1		17			17	17	100
All results	CVP >>>	17	100	Positive			
Sample B1		17			17	17	100
All results	CVP >>>	17	100	Negative			
(572) ANA screening (antibodies against cell nucleus) - semi-quantity		10			0		
Sample A1		10			0		
All results		± 1	10	titre 40			
		± 6	60	titre 1280			
		± 3	30	titre 2560			
Sample B1		10			0		
All results		± 1	10	Not specified			
		± 3	30	titre 0 (not measurable)			
		± 3	30	titre 40			
		± 2	20	titre 80			
		± 1	10	titre 2560			
(561) ANA - type of fluorescence - nucleus		13			13	11	85
Sample A1		13			13	11	85
All results		1	7,7	DFS 70 (AC-2); Fine or coarse speckled or nuclear matrix (AC-4/AC-5)			
	CVP >>>	11	85	Fine or coarse speckled or nuclear matrix (AC-4/AC-5)			
		1	7,7	Fine or coarse speckled or nuclear matrix (AC-4/AC-5); No fluorescence (AC-0)			
Sample B1		13			13	13	100
All results	CVP >>>	13	100	No fluorescence (AC-0)			
(563) ANA screening (antibodies against cytoplasm) - prove		13			13	13	100
Sample A1		13			13	13	100
All results	CVP >>>	12	92	Negative			
	>	1	7,7	Inconclusive result (borderline)			
Sample B1		13			13	13	100
All results	CVP >>>	13	100	Negative			
(573) ANA screening (antibodies against cytoplasm) - semi-quantity		9			0		
Sample A1		9			0		
All results		± 3	33	titre 0 (not measurable)			
		± 3	33	titre 40			
		± 2	22	titre 80			
		± 1	11	titre 2560			
Sample B1		9			0		
All results		± 3	33	titre 0 (not measurable)			
		± 3	33	titre 40			
		± 2	22	titre 80			
		± 1	11	titre 2560			
(564) ANA - type of fluorescence - cytoplasm		12			12	12	100
Sample A1		12			12	12	100
All results	CVP >>>	11	92	No fluorescence (AC-0)			
	>	1	8,3	Dense or fine speckled cytoplasm (AC-19/AC-20)			
Sample B1		12			12	12	100
All results	CVP >>>	12	100	No fluorescence (AC-0)			
Set 2							
(565) ANCA imunofluorescence - prove		9			9	9	100
Sample A2		9			9	9	100
All results	CVP >>>	9	100	Negative			
Sample B2		9			9	9	100
All results	CVP >>>	9	100	Positive			
(574) ANCA IF (ethanol) - semi-quantity		5			0		
Sample A2		5			0		
All results		± 1	20	titre 0 (not measurable)			
		± 3	60	titre 20			

EQA round: AIM2/24 - Autoimmunity

Deadline: 27.9.2024

Setup: Slovakia

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
	±	1	20	titre 40			
Sample B2		5					0
All results	±	2	40	titre 20			
	±	1	20	titre 40			
	±	2	40	titre 640			
(578) ANCA IF (formalin) - semi-quantity		5					0
Sample A2		5					0
All results	±	1	20	titre 0 (not measurable)			
	±	3	60	titre 20			
	±	1	20	titre 40			
Sample B2		5					0
All results	±	2	40	titre 20			
	±	1	20	titre 40			
	±	1	20	titre 80			
	±	1	20	titre 320			
(566) ANCA - type of fluorescence		8			8	7	88
Sample A2		8			8	8	100
All results	CVP >>>	8	100	Fluorescence ANCA not present			
Sample B2		8			8	7	88
All results	CVP >>>	7	88	Perinuclear fluorescence			
		1	13	Cytoplasmic granular fluorescence			
(569) anti-myeloperoxidase		16			16	15	94
Sample A2		16			16	16	100
All results	CVP >>>	16	100	Negative			
Sample B2		16			16	15	94
All results	CVP >>>	1	6,3	Negative			
		15	94	Positive			
(570) anti-proteinase III		16			16	15	94
Sample A2		16			16	16	100
All results	CVP >>>	16	100	Negative			
Sample B2		16			16	15	94
All results	CVP >>>	15	94	Negative			
		1	6,3	Positive			
Set 3							
(585) anti-centromere		14			14	14	100
Sample A3		14			14	14	100
All results	CVP >>>	14	100	Negative			
Sample B3		14			14	14	100
All results	CVP >>>	14	100	Negative			
(584) anti-ENA, antigen Jo-1		15			15	15	100
Sample A3		15			15	15	100
All results	CVP >>>	15	100	Negative			
Sample B3		15			15	15	100
All results	CVP >>>	15	100	Negative			
(583) anti-ENA, antigen RNP		15			15	15	100
Sample A3		15			15	15	100
All results	CVP >>>	15	100	Positive			
Sample B3		15			15	15	100
All results	CVP >>>	15	100	Negative			
(582) anti-ENA, antigen Scl-70		15			15	15	100
Sample A3		15			15	15	100
All results	CVP >>>	15	100	Negative			
Sample B3		15			15	15	100
All results	CVP >>>	15	100	Negative			
(580) anti-ENA, antigen SS-A/Ro-60		15			15	15	100
Sample A3		15			15	15	100
All results	CVP >>>	15	100	Positive			
Sample B3		15			15	15	100
All results	CVP >>>	15	100	Negative			
(581) anti-ENA, antigen SS-B/La		15			15	15	100
Sample A3		15			15	15	100
All results	CVP >>>	15	100	Positive			
Sample B3		15			15	15	100
All results	CVP >>>	15	100	Negative			
Set 4							
(588) anti-dsDNA immunofluorescence - prove		7			7	7	100
Sample A4		7			7	7	100
All results	CVP >>>	7	100	Negative			

EQA round: AIM2/24 - Autoimmunity

Deadline: 27.9.2024

Setup: Slovakia

Test Sample Group	Frequency of the results				Success			
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
Sample B4		7				7	7	100
All results	CVP >>>	7	100	Positive				
(577) anti-dsDNA immunofluorescence - semi-quantity		6				0		
Sample A4		6				0		
All results	±	2	33	titre 0 (not measurable)				
	±	4	67	titre 10				
Sample B4		6				0		
All results	±	2	33	titre 10				
	±	2	33	titre 320				
	±	2	33	titre 640				
(589) anti-dsDNA other methods		13				13	13	100
Sample A4		13				13	13	100
All results	CVP >>>	13	100	Negative				
Sample B4		13				13	13	100
All results	CVP >>>	13	100	Positive				
Set 5								
(591) anti-nukleosomes IgG		12				12	11	92
Sample A5		12				12	12	100
All results	CVP >>>	12	100	Negative				
Sample B5		12				12	11	92
All results		1	8,3	Negative				
	CVP >>>	11	92	Positive				